Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Uses of WNK kinase inhibitors in prevention and/or treatment of pulmonary hypertension

A kinase inhibitor and pulmonary arterial hypertension technology, applied in the field of medicine, can solve problems such as the lack of a cure for pulmonary arterial hypertension, the uncurable mortality rate of pulmonary arterial hypertension, etc.

Inactive Publication Date: 2019-12-20
GENERAL HOSPITAL OF PLA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although these drugs can alleviate the symptoms of PAH to a certain extent, pulmonary hypertension is still an incurable disease with a high mortality rate. The median survival time of patients under treatment is only 2.7 years. Therefore, it is particularly urgent to find new specific therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of WNK kinase inhibitors in prevention and/or treatment of pulmonary hypertension
  • Uses of WNK kinase inhibitors in prevention and/or treatment of pulmonary hypertension
  • Uses of WNK kinase inhibitors in prevention and/or treatment of pulmonary hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] 1. Materials and methods

[0079] 1.1 Animals

[0080] 70 SD rats (about 200 g, male, SPF grade) were purchased from Beijing Weitong Lihua Experimental Animal Co., Ltd., license number: SCXK (Beijing) 2016-0006. Raise under constant temperature and humidity conditions, give full-price nutritional feed regularly, room temperature 22-25 ℃, humidity 50%-70%.

[0081] 1.2 Reagents and samples

[0082] WNK463 powder, available from selleck;

[0083] DMSO, purchased from solaxbio;

[0084] PEG300, purchased from source leaf organisms;

[0085] Tween 80, purchased from Meilun Biology;

[0086] Monocrotaline (MCT) powder was purchased from Sigma.

[0087] Solvent for WNK463: 5% DMSO+30% PEG300+5% Tween 80+60% double distilled water, pH=7.

[0088] Solvent for MCT: 1M HCl+NaOH+double distilled water, pH=7.

[0089] 1.3 Instruments

[0090] Small animal ventilator (kent scientific, USA);

[0091] Multifunctional Physiological Apparatus (Millar, USA);

[0092] Small Ani...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses uses of WNK kinase inhibitors in prevention and / or treatment of pulmonary hypertension, and particularly uses of WNK 463 in the prevention and / or treatment of pulmonary hypertension and complications thereof. Experiments by inventors of the present application find that the WNK kinase inhibitors (especially the WNK 463) show relatively good effects on protection of pulmonic circulation-right-heart pressure and function, right ventricular hypertrophy, etc. of monocrotaline (MCT)-induced pulmonary hypertension in rats, and have potential value of being developedinto drugs for the prevention and treatment of pulmonary hypertension and complications thereof.

Description

technical field [0001] The present invention relates to the field of medical technology, in particular to the use of a WNK kinase inhibitor in the preparation of products for the prevention and / or treatment of pulmonary hypertension and its complications, especially the use of WNK463 in the preparation of products for the prevention and / or treatment of pulmonary hypertension and its complications use in the product. Background technique [0002] Pulmonary arterial hypertension (PAH) refers to a hemodynamic and pathophysiological state in which the pulmonary artery pressure rises above a certain threshold. The etiology is complex and is caused by a variety of heart, lung or pulmonary vascular diseases. Failure can be an independent disease, a complication, or a syndrome. The diagnostic criteria of hemodynamics are: the average pulmonary artery pressure detected by right heart catheterization is ≥25mmHg at resting state at sea level. [0003] Pulmonary hypertension is divide...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4545A61P11/00A61P9/12A61P7/02A61P9/04A61P9/00A23L33/10
CPCA61K31/4545A61P11/00A61P9/12A61P7/02A61P9/04A61P9/00A23L33/10A23V2002/00A23V2200/314A23V2200/326A23V2250/30
Inventor 何昆仑张泽宇刘春蕾高晓健李鑫李晨韦清霞李寒露
Owner GENERAL HOSPITAL OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com